Methods of treatment of cholestatic diseases
The present invention relates to the use of compound 1-[4-methylthiophenyl]-3-[3,5-dimethyl-4-carboxydimethyl-methyloxyphenyl]prop-2-en-1-one (Elafibranor or GFT505) for treating cholestatic diseases, and more specifically PBC and/or PSC.
1. A method for treating primary biliary cholangitis (PBC), the method comprising administering to a subject having PBC and inadequate response to ursodeoxycholic acid a therapeutically effective amount of a composition comprising elafibranor.
2. The method according to claim 1 , wherein said composition is formulated in a form selected from the group consisting of an injectable suspension, a gel, an oil, a pill, a suppository, a powder, a gel cap, a capsule, an aerosol, and a galenic form or device assuring a prolonged and/or slow release.
3. The method according to claim 1 , wherein elafibranor is administered orally once daily at a dose of 80 or 120 mg/day.
4. The method according to claim 1 , wherein elafibranor is administered at a dose of 70 mg to 130 mg per administration.
5. The method according to claim 1 , wherein elafibranor is administered at a dose of 80 mg per administration.
6. The method according to claim 5 , wherein elafibranor is administered orally.
7. The method according to claim 1 , wherein elafibranor is administered at a dose of 120 mg per administration.
8. The method according to claim 7 , wherein elafibranor is administered orally.
9. The method according to claim 1 , wherein elafibranor is administered orally once daily at a dose of 80 mg.
10. The method according to claim 1 , wherein elafibranor is administered orally once daily at a dose of 120 mg.